DK2471954T3 - Genetiske modtagelighedsvarianter forbundet med kardiovaskulære sygdomme - Google Patents

Genetiske modtagelighedsvarianter forbundet med kardiovaskulære sygdomme Download PDF

Info

Publication number
DK2471954T3
DK2471954T3 DK11194162.1T DK11194162T DK2471954T3 DK 2471954 T3 DK2471954 T3 DK 2471954T3 DK 11194162 T DK11194162 T DK 11194162T DK 2471954 T3 DK2471954 T3 DK 2471954T3
Authority
DK
Denmark
Prior art keywords
risk
markers
allele
disease
marker
Prior art date
Application number
DK11194162.1T
Other languages
English (en)
Inventor
Gudmar Thorleifsson
Anna Helgadottir
Andrei Manolescu
Original Assignee
Decode Genetics Ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decode Genetics Ehf filed Critical Decode Genetics Ehf
Application granted granted Critical
Publication of DK2471954T3 publication Critical patent/DK2471954T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Claims (8)

1. In v/'tro-fremgangsmåde til bestemmelse af modtageligheden for en arteriel sygdom i et humant individ, hvilken fremgangsmåde omfatter bestemmelse af tilstedeværelse eller fravær af mindst et allel af mindst en polymorf markør i en nukleinsyreprøve, der er opnået fra individet, hvori det mindst ene allel af den mindste ene polymorfe markør er valgt blandt de polymorfe markører rsl0757278 (SEQ ID NO:88) allel G, rsl0116277 (SEQ ID NO:56) allel T, rsl333040 (SEQ ID NO:59) allel T og rs2383207 (SEQ ID NO:82) allel G, and korrelerede markører i sammenkædnings-uligevægt dermed lokaliseret inden for sammenkædnings-uligevægtsblokken på kromosom 9 med sekvensen som angivet i SEQ ID NO:94, hvilke er kendetegnet ved værdier på r2 > 0,2 og er valgt fra gruppen bestående af markørerne angivet i Tabel 3 og Tabel 21, og hvori tilstedeværelsen af det mindste ene allel er indikativ for modtageligheden af arteriel sygdom.
2. Fremgangsmåden ifølge krav 1, hvilken fremgangsmåde yderligere omfatter vurdering af mindst én biomarkør i en prøve fra individet.
3. Fremgangsmåden ifølge krav 2, hvori biomarkøren er en kardiel markør eller en inflammatorisk markør.
4. Fremgangsmåden ifølge krav 2 eller krav 3, hvori den mindst ene markør er valgt blandt creatin-kinase, troponin, glycogen-phosphorylase, C-reactivt protein (CRP), serum amyloid A, fibrinogen, interleukin-6, vævsnekrose-faktor-alfa, opløselige vaskulære celleadhæsionsmolekyler (sVCAM), opløselige intervasculære adhæsionsmolekyler (sICAM), E-selectin, matrix-metalloprotease type-1, matrix-metalloprotease type-2, matrix-metalloprotease type-3, matrix-metalloprotease type-9, serum sCD40L, leukotriener, leukotrien-metabolitter, interleukin-6, vævsnekrose-faktor-alfa, myeloperoxidase (MPO), og N-tyrosin.
5. Fremgangsmåden ifølge krav 4, hvori leukotrienen er valgt blandt LTB4, LTC4, LTD4 og LTE4.
6. Fremgangsmåden ifølge et hvilket som helst af de foregående krav, hvori den arterielle sygdom er valgt fra gruppen bestående af myokardie-infarkt, koronaarteriesygdom, akut koronart syndrome, slagtilfælde, perifer arteriel sygdom, restenose, intrakraniel aneurisme og aorta abdominal aneurisme.
7. Fremgangsmåden ifølge krav 6, hvori myokardie-infarktet har tidlig indtræden.
8. Fremgangsmåden ifølge krav 7, hvori den tidlige indtræden er før en alder af 50 for mænd og før en alder af 60 for kvinder.
DK11194162.1T 2007-02-21 2008-02-21 Genetiske modtagelighedsvarianter forbundet med kardiovaskulære sygdomme DK2471954T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IS8613 2007-02-21
IS8640 2007-04-30
IS8701 2007-12-21
EP08710293A EP2115172A1 (en) 2007-02-21 2008-02-21 Genetic susceptibility variants associated with cardiovascular disease

Publications (1)

Publication Number Publication Date
DK2471954T3 true DK2471954T3 (da) 2016-09-12

Family

ID=39432938

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11194162.1T DK2471954T3 (da) 2007-02-21 2008-02-21 Genetiske modtagelighedsvarianter forbundet med kardiovaskulære sygdomme

Country Status (16)

Country Link
US (2) US9617597B2 (da)
EP (2) EP2115172A1 (da)
JP (1) JP5646179B2 (da)
KR (1) KR101571523B1 (da)
CN (1) CN101668865B (da)
AU (1) AU2008218542B2 (da)
BR (1) BRPI0807927A2 (da)
CA (1) CA2679581C (da)
DK (1) DK2471954T3 (da)
EA (1) EA022610B1 (da)
HU (1) HUE030996T2 (da)
IL (1) IL200453A (da)
MX (1) MX2009008878A (da)
NZ (1) NZ579445A (da)
SG (1) SG178811A1 (da)
WO (1) WO2008102380A1 (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7883851B2 (en) 2007-05-02 2011-02-08 Board Of Regents, The University Of Texas System Common allele on chromosome 9 associated with coronary heart disease
AU2009205956B2 (en) 2008-01-18 2015-07-02 President And Fellows Of Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
US20090221620A1 (en) * 2008-02-20 2009-09-03 Celera Corporation Gentic polymorphisms associated with stroke, methods of detection and uses thereof
ES2344396B1 (es) * 2009-02-24 2011-06-24 Fina Biotech Slu Marcadores geneticos del riesgo de sufrir reestenosis.
WO2010131268A1 (en) * 2009-05-11 2010-11-18 Decode Genetics Ehf Genetic variants for basal cell carcinoma, squamous cell carcinoma and cutaneous melanoma
EP2264183B1 (en) * 2009-06-09 2016-12-07 Gendiag.exe, S.L. Risk markers for cardiovascular disease
CN102803951A (zh) * 2009-06-15 2012-11-28 心脏Dx公司 冠状动脉疾病风险的测定
WO2011159157A1 (en) * 2010-06-15 2011-12-22 Cellagenics B.V. Novel intergenic elements for enhancing gene expression
EP2596349B1 (en) 2010-07-23 2017-12-13 President and Fellows of Harvard College Methods of detecting cardiovascular diseases or conditions
SG10201505724SA (en) 2010-07-23 2015-09-29 Harvard College Methods of detecting diseases or conditions using phagocytic cells
MX361944B (es) 2010-07-23 2018-12-19 President And Fellows Of Harvard College Star Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales.
EP2596353A4 (en) 2010-07-23 2014-01-15 Harvard College METHOD FOR DETECTING PRENATAL OR PREGNANT DISEASES OR SUFFERING
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
EP2640857A4 (en) * 2010-11-18 2014-04-30 Decode Genetics Ehf GENETIC RISK FACTORS OF SINUS NODE SYNDROME
WO2012135657A2 (en) * 2011-03-31 2012-10-04 Yale University Compositions and methods for diagnosis, preventing and treating intracranial aneurysms
DK2554679T3 (da) * 2011-08-05 2016-04-04 Gendiag Exe Sl Genetiske markører til risikovurdering for hjertekarsygdom
WO2013032883A2 (en) * 2011-08-26 2013-03-07 Ottawa Heart Institute Research Corporation Methods of detecting and treating cardiovascular diseases
AU2013274002A1 (en) 2012-06-15 2015-02-05 Harry Stylli Methods of detecting diseases or conditions
KR20150035818A (ko) 2012-06-15 2015-04-07 해리 스타일리 순환 병든 세포를 사용하여 질환 또는 병태를 검출하는 방법
MD707Z (ro) * 2013-01-18 2014-07-31 Институт Зоологии Академии Наук Молдовы Metodă de identificare a secvenţelor polimorfe 4a/4b ale genei sintetazei endoteliale a oxidului nitric
EP2965086A4 (en) 2013-03-09 2017-02-08 Harry Stylli Methods of detecting prostate cancer
US10494675B2 (en) 2013-03-09 2019-12-03 Cell Mdx, Llc Methods of detecting cancer
WO2014175287A1 (ja) * 2013-04-26 2014-10-30 国立大学法人 京都大学 脳動脈瘤の形成および／または増大の抑制若しくは縮小用医薬組成物
KR101602688B1 (ko) 2013-12-30 2016-03-11 가톨릭관동대학교산학협력단 microRNA-365 활성화제를 포함하는 혈관평활근세포 증식 또는 이동 억제용 약학적 조성물
CN104946731B (zh) * 2014-03-28 2019-12-20 中国中医科学院中药研究所 快速检测金银花的pcr试剂盒及检测方法
WO2016040843A1 (en) 2014-09-11 2016-03-17 Harry Stylli Methods of detecting prostate cancer
WO2016123163A2 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
RU2627643C2 (ru) * 2015-08-18 2017-08-09 Государственное бюджетное учреждение "Академия наук Республики Саха(Якутия)" (ГБУ АН РС(Я) Способ прогнозирования риска субарахноидального кровоизлияния вследствие разрыва аневризмы сосудов головного мозга у лиц азиатской расы
CN106811520A (zh) * 2016-08-17 2017-06-09 上海易瑞生物科技有限公司 一种心肌梗死易感基因检测分型试剂盒及其应用
RU2693997C2 (ru) * 2017-12-04 2019-07-08 Федеральное Государственное Бюджетное Научное Учреждение "Федеральный Научно-Клинический Центр Реаниматологии И Реабилитологии" (Фнкц Рр) Способ определения степени предрасположенности к сердечно-сосудистым заболеваниям
CN108342472A (zh) * 2018-04-13 2018-07-31 东华大学 一种冠心病易感基因检测分型试剂盒
US10468141B1 (en) 2018-11-28 2019-11-05 Asia Genomics Pte. Ltd. Ancestry-specific genetic risk scores
CN113767179A (zh) * 2018-12-13 2021-12-07 国立研究开发法人国立循环器病研究中心 脑梗塞发病风险预测方法
CN109486940A (zh) * 2018-12-25 2019-03-19 北京北基医学检验实验室有限公司 一种扩增颅内动脉肿瘤相关基因的引物组及检测试剂盒
CN109628577A (zh) * 2019-01-07 2019-04-16 杭州艾迪康医学检验中心有限公司 检测冠状动脉硬化相关单核苷酸多态性位点的引物和方法
KR102158720B1 (ko) * 2019-04-03 2020-09-22 한림대학교 산학협력단 Lrrc3 유전자의 단일염기다형성을 포함하는 뇌동맥류 진단용 snp 마커
KR102158714B1 (ko) * 2019-04-03 2020-09-22 한림대학교 산학협력단 Tcf24 유전자의 단일염기다형성을 포함하는 뇌동맥류 진단용 snp 마커
RU2719914C1 (ru) * 2019-12-06 2020-04-23 федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ прогнозирования исходов операций коронарного шунтирования
KR102366097B1 (ko) * 2021-05-03 2022-02-23 주식회사 바이오에이지 임상 및 유전변이 정보를 통합한 한국인 뇌혈관 질환 예측 방법 및 관련 검사추천방법
KR102344173B1 (ko) * 2021-05-03 2021-12-29 주식회사 바이오에이지 임상 및 유전변이 정보를 통합한 한국인 관상동맥 질환 예측 방법 및 관련 검사추천방법
CN113484453B (zh) * 2021-07-07 2022-08-09 天津中医药大学 一种缺血性脑卒中预警方法
CN114672548B (zh) * 2022-03-10 2024-04-19 华捷生物科技(青岛)有限公司 一种人类静脉血栓风险基因pai-1，thbd和proc基因多态性检测试剂盒及其制备方法和应用
WO2023205243A1 (en) * 2022-04-19 2023-10-26 The Regents Of The University Of Michigan Determining risk of fibromuscular dysplasia and systems and methods of use thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
ATE167524T1 (de) 1983-01-10 1998-07-15 Gen Probe Inc Verfahren zum nachweis, identifizieren und quantifizieren von organismen und viren
US5288611A (en) 1983-01-10 1994-02-22 Gen-Probe Incorporated Method for detecting, identifying, and quantitating organisms and viruses
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
JP3771253B2 (ja) 1988-09-02 2006-04-26 ダイアックス コープ． 新規な結合タンパク質の生成と選択
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5288644A (en) 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
EP0562025B1 (en) 1990-12-06 2001-02-07 Affymetrix, Inc. (a Delaware Corporation) Compounds and their use in a binary synthesis strategy
CA2105300C (en) 1991-03-01 2008-12-23 Robert C. Ladner Process for the development of binding mini-proteins
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
CN1141398C (zh) * 2000-03-28 2004-03-10 陈高明 一种多基因扩增芯片及其制备方法
USH2191H1 (en) * 2000-10-24 2007-06-05 Snp Consortium Identification and mapping of single nucleotide polymorphisms in the human genome
USH2220H1 (en) * 2001-08-10 2008-07-01 Snp Consortium Identification and mapping of single nucleotide polymorphisms in the human genome
US20040267458A1 (en) * 2001-12-21 2004-12-30 Judson Richard S. Methods for obtaining and using haplotype data
WO2004035746A2 (en) * 2002-10-17 2004-04-29 Decode Genetics Ehf. Susceptibility gene for myocardial infarction
EP1613774A2 (en) * 2003-03-10 2006-01-11 Applera Corporation Genetic polymorphisms associated with stenosis, methods of detection and uses thereof
CA2832293C (en) * 2003-11-26 2015-08-04 Celera Corporation Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof
US20050191678A1 (en) * 2004-02-12 2005-09-01 Geneob Usa Inc. Genetic predictability for acquiring a disease or condition
JP2009521905A (ja) * 2004-03-05 2009-06-11 アプレラ コーポレイション 冠動脈心疾患に関連する遺伝的多型、その検出方法および使用
CA2566257A1 (en) * 2004-05-07 2005-11-24 Applera Corporation Genetic polymorphisms associated with vascular diseases, methods of detection and uses thereof
US20060004526A1 (en) * 2004-07-01 2006-01-05 Ambion, Inc. System and method for processing results of a complex genetic test
US20080131887A1 (en) * 2006-11-30 2008-06-05 Stephan Dietrich A Genetic Analysis Systems and Methods
US7883851B2 (en) 2007-05-02 2011-02-08 Board Of Regents, The University Of Texas System Common allele on chromosome 9 associated with coronary heart disease

Also Published As

Publication number Publication date
US20100068705A1 (en) 2010-03-18
MX2009008878A (es) 2009-08-28
IL200453A0 (en) 2010-04-29
KR20090117896A (ko) 2009-11-13
EA200970781A1 (ru) 2010-04-30
EP2471954A1 (en) 2012-07-04
CN101668865A (zh) 2010-03-10
IL200453A (en) 2014-12-31
BRPI0807927A2 (pt) 2014-06-24
CA2679581A1 (en) 2008-08-28
SG178811A1 (en) 2012-03-29
CN101668865B (zh) 2015-05-06
EP2471954B1 (en) 2016-08-24
US9617597B2 (en) 2017-04-11
KR101571523B1 (ko) 2015-11-24
CA2679581C (en) 2020-12-22
JP2010518848A (ja) 2010-06-03
EP2115172A1 (en) 2009-11-11
EA022610B1 (ru) 2016-02-29
NZ579445A (en) 2012-02-24
JP5646179B2 (ja) 2014-12-24
US20120208709A1 (en) 2012-08-16
AU2008218542B2 (en) 2014-06-26
AU2008218542A1 (en) 2008-08-28
HUE030996T2 (en) 2017-06-28
WO2008102380A1 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
DK2471954T3 (da) Genetiske modtagelighedsvarianter forbundet med kardiovaskulære sygdomme
KR101582321B1 (ko) 심장성 부정맥의 위험 관리를 위한 유전적 마커
CN101874120B (zh) 作为用于乳腺癌风险评估、诊断、预后和治疗的标记的chr2和chr16的遗传性变型
KR101374304B1 (ko) 타입 2 당뇨병의 위험에 대한 진단 마커인 ｔｃｆ7ｌ2유전자의 유전적 변이체
CN101641451A (zh) chr8q24.21上的癌症易感性变体
KR20110036608A (ko) 유방암 위험도 평가를 위한 유전적 변이
KR20100017865A (ko) 유방암의 위험도 평가, 진단, 예후 및 치료용 마커인 염색체 ５ｐ１２ 및 염색체 １０ｑ２６ 상의 유전적 변이
US20090305284A1 (en) Methods for Identifying Risk of Breast Cancer and Treatments Thereof
US20170073737A1 (en) Biomarkers and combinations thereof for diagnosing tuberculosis
KR20110081807A (ko) 갑상선암의 위험도 평가를 위해 유용한 유전적 변이
KR20110015409A (ko) 염증성 장 질환에 대한 유전자 발현 마커
KR102481305B1 (ko) 유전자에 기반한 염증성 장 질환의 진단
AU2016325030A1 (en) Novel biomarkers and methods of treating cancer
WO2006022629A1 (en) Methods of identifying risk of type ii diabetes and treatments thereof
KR20090087486A (ko) 타입 ２ 당뇨병의 유전적 감수성 변이
CN101631876A (zh) 2型糖尿病的遗传易感性变体
WO2005097421A2 (en) Methods for identifying risk of osteoarthritis and treatments thereof
CA2497597A1 (en) Methods for identifying subjects at risk of melanoma and treatments
IL179831A (en) In vitro method for detecting the presence or possibility of autism or autism disorder, and in vitro method for selecting compounds with biological activity on autism or autism disorders
KR20170116009A (ko) 전립선암의 진단을 위한 신규한 rna-바이오마커 시그니처
WO2006022636A1 (en) Methods for identifying risk of type ii diabetes and treatments thereof
KR20190126812A (ko) 질환 진단용 바이오마커
TW202227102A (zh) 治療脂肪肝病之方法
AU2017209307A1 (en) Compositions and methods for screening and identifying clinically aggressive prostate cancer
WO2006022638A1 (en) Methods for identifying risk of type ii diabetes and treatments thereof